Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Acetaminophen Access Limitations To Be Considered By FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is considering examining more extensive ways to inform consumers about the dangers of acetaminophen as well as techniques to limit access to OTC drugs containing the analgesic ingredient.

Related Content

Barriers To Making Acetaminophen Changes Form Basis For Opposition
Acetaminophen-Linked Acute Liver Failure Cases 57% Accidental In Study
OTC Analgesic Additional Safety Labeling To Be Considered By NDAC
Acetaminophen Toxicity Headed To NDAC, New FDA Drug Safety Group
Pediatric Acetaminophen Toxicity Literature Distribution Supported By AAP
Acetaminophen/Acetylcysteine Combo Efficacy Testing Urged In BMJ Letter
Acetaminophen, Aspirin Not Linked To Kidney Disease Risk - JAMA Study
Acetaminophen/NSAID Relative Liver Risks Well Known By MDs, Survey Shows
UK Acetaminophen Deaths Decline 21% After Packaging Changes
FDA Solicits Databases To Track Infrequent, Rare Drug AEs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts